PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE

A recent study conducted in Salt Lake City on July 9, 2026, has underscored the efficacy of screening procedures and the potential for cost savings within a significant underserved population. Sera Prognostics Inc., known as The Pregnancy Company® and listed on Nasdaq as SERA, is committed to enhancing the health outcomes of both mothers and newborns through groundbreaking innovations. This research has shed light on the importance of efficient screening methods that could lead to substantial financial benefits for a large segment of the population.